Table 1 Demographic and clinical characteristics of patients
From: Addiction potential of phentermine prescribed during long-term treatment of obesity
APT (N=152) | LPT (N=117) | Significant difference a | |
|---|---|---|---|
Asked, consented, completed, (LTP) withdrawal completed | 158, 152, 152 | 124, 117, 117, 76 | |
Mean (s.d.) | Mean (s.d.) | ||
Age | 44.18 (12.39) | 51.18 (11.40) | t=−4.757, df=267, P<0.001 |
BMI | 34.88 (7.31) | 33.79 (7.59) | t=1.198, df=267, P=0.232 |
Days of phentermine treatment | 9.30 (3.35) | ||
Years of phentermine treatment | 8.35 (5.16) | ||
Rx Duration, Range (days/years) | 4–22 | 1.1–21.5 | |
Phentermine-HCl (mg) | 34.46 (9.23) | 53.43 (19.46) | t=−9.732, df=267, P<0.001 |
Phentermine dose range (mg/d) | 15–93.75 | 18.75–112.5 | |
Number of office examinations | 72.1 (51.7) | ||
Patients who had taken treatment hiatus<1 month | 117 (100%) | ||
Patients who had taken treatment hiatus>1 month | 70 (60%) | ||
Average treatment hiatus (mo) | 19.5 (19.9) | ||
N (%) | N (%) | ||
Sex (female) | 134 (88.2) | 108 (92.3) | χ2=1.261, df=1, P=0.261 |
Race | |||
White | 138 (90.8) | 103 (88.0) | χ2=1.812, df=3, P=0.612 |
Hispanic | 10 (6.6) | (7.7) | |
Black | 1 (0.7) | (2.6) | |
Asia | 3 (2.0) | 2 (1.7) | |
Concomitant antidepressant | 2 (1.3) | 24 (20.5) | |
Bupropion | 3 | ||
Citalopram | 5 | ||
Desvenlafaxine | 1 | ||
Duloxetine | 1 | ||
Escitalopram | 5 | ||
Fluoxetine | 4 | ||
Paroxetine | 1 | ||
Sertraline | 2 | ||
Trazodone | 3 | ||
Venlafaxine | 1 | ||
Other antiobesity medications | 0 | 6 (5.1) | |
Topiramate | 4 | ||
Diethylpropion | 2 | ||
